Antibody responses to SARS-CoV-2 in patients with COVID-19
Quan-Xin Long 1, Bai-Zhong Liu 2, Hai-Jun Deng 1, Gui-Cheng Wu 3 4, Kun Deng 5, Yao-Kai Chen 6, Pu Liao 7, Jing-Fu Qiu 8, Yong Lin 1, Xue-Fei Cai 1, De-Qiang Wang 1, Yuan Hu 1, Ji-Hua Ren 1, Ni Tang 1, Yin-Yin Xu 2, Li-Hua Yu 2, Zhan Mo 2, Fang Gong 2, Xiao-Li Zhang 2, Wen-Guang Tian 2, Li Hu 2, Xian-Xiang Zhang 3 4, Jiang-Lin Xiang 3 4, Hong-Xin Du 3 4, Hua-Wen Liu 3 4, Chun-Hui Lang 3 4, Xiao-He Luo 3 4, Shao-Bo Wu 3 4, Xiao-Ping Cui 3 4, Zheng Zhou 3 4, Man-Man Zhu 5, Jing Wang 6, Cheng-Jun Xue 6, Xiao-Feng Li 6, Li Wang 6, Zhi-Jie Li 7, Kun Wang 7, Chang-Chun Niu 7, Qing-Jun Yang 7, Xiao-Jun Tang 8, Yong Zhang 8, Xia-Mao Liu 9, Jin-Jing Li 9, De-Chun Zhang 10, Fan Zhang 10, Ping Liu 11, Jun Yuan 1, Qin Li 12, Jie-Li Hu 13, Juan Chen 14, Ai-Long Huang 15
PMID: 32350462
Nat Med2020 Jun;26(6):845-848.
doi: 10.1038/s41591-020-0897-1. Epub 2020 Apr 29.
Abstract
We report acute antibody responses to SARS-CoV-2 in 285 patients with COVID-19. Within 19 days after symptom onset, 100% of patients tested positive for antiviral immunoglobulin-G (IgG). Seroconversion for IgG and IgM occurred simultaneously or sequentially. Both IgG and IgM titers plateaued within 6 days after seroconversion. Serological testing may be helpful for the diagnosis of suspected patients with negative RT-PCR results and for the identification of asymptomatic infections.
